ADIL AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock has a low value rating. If your investment strategy is value-oriented and you have long-term positions, it's crucial to adhere to your exit plan and consider reducing holdings.
ADIL Current Performance
-10.26%
Adial pharmaceuticals inc
1.19%
Avg of Sector
1.11%
S&P500
Top 10 High Relevance to ADIL
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
JANX | Janux therapeutics inc | - | 3 | 3 | 3 | 1 | |
VTVT | Vtv therapeutics inc | - | 3 | 3 | 1 | 1 | |
VKTX | Viking therapeutics inc | 2 | 4 | 2 | 3 | 1 | |
ACRV | Acrivon therapeutics inc | - | 4 | 2 | 1 | 1 | |
CRDF | Cardiff oncology inc | 3 | 2 | 2 | 1 | 1 |
- JANX Janux therapeutics incValue -Trend 3Swing Trading 3Whale Interest 3Dividend 1See more
ADIL Profile
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of treatments for addictions and related disorders. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients. AD04 is investigated in the Company's ONWARD pivotal Phase III clinical trial for the treatment of AUD in subjects with certain target genotypes (estimated to be approximately one-third of the AUD population) identified using the Company's companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company's wholly owned subsidiary is Purnovate, Inc.